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Abstract: The underlying problem for two of 
the three most common patterns of 
unexpected hospital deaths (PUHD) is 
hypoventilation1. Current methods of post-
operative respiratory monitoring give 
delayed signals and have a high false 
positive rate leading nurses to ignore 
alarms. We hypothesize there exists a 
combination of low cost sensors which are 
capable of providing real time feedback and 
alarms regarding obstructive sleep apnea 
and ventilatory depression. Such a monitor 
would be useful during space travel when 
monitoring personnel are limited following 
an injury or if astronauts were to be sedated 
during extended travel. Methods: Twenty-six 
subjects will be recruited to participate in a 
study of the effects of Propofol and 
Remifentanil. Throughout the day, these 
patients will be exposed to varying levels of 
both drugs simultaneously via target 
controlled infusions. These patients will be 
attached to breathing and oxygen monitors 
including chest bands, pulse oximeters, 
nasal pressure sensors, C02 capnography, 
breathing microphones, and thermistors.  
The patients are then observed for types of 
apnea or ventilatory depression. Results: 
The study is currently ongoing however 
preliminary analyses of the data indicate 
multiple low cost sensors are capable of 
detecting breathing as well as obstructive 
events and apnea. Conclusion: Using only a 
combination of low cost sensors, we can 
provide real time respiratory event data to 
nurses and practitioners. 
 
INTRODUCTION & BACKGROUND 
The underlying problem for two of the three 
most common patterns of unexpected 
hospital deaths (PUHD) is hypoventilation1. 
Type II PUHD (CO2 narcosis) involves a 
reduction in respiratory rate and/or tidal 
volume, and if supplemental oxygen is 
being provided, a pulse oximeter will not 
detect the problem until the hypercarbia is 
significantly advanced and the patient is 
near respiratory arrest. Type III PUHD is 
induced by obstructive sleep apnea in the 
presence of arousal failure, and is 
recognized as a repetitive sequence of 
cyclic apneas and self-arousals which 
precede the final apnea. A pulse oximeter 
alarms with each apneic period and will 
likely be interpreted as generating many 
false positive alarms.1 The risk of opioid-
induced respiratory depression in 
postoperative patients is greatest in the first 
24 hours after initiation of opioids2, and 
opioids are the most commonly used drug 
for treating pain in the postoperative 
period.3 
These problems would be especially 
apparent in space travel where monitoring 
personnel are limited due to either sedation 
of crew members or an injury rendering the 
crew short-handed. 
Respiratory depression is caused by drug-
induced inhibition of the breathing control 
center of the brain stem. Partial to full 
airway obstruction is an anatomic problem 
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involving the soft palate, tongue base, 
and/or epiglottis, caused by drug-induced 
decreases in airway patency and muscle 
tone. Sedatives and opioids depress the 
response to elevated CO2 (reduced drive to 
breathe), worsen arousal, cause airway 
obstruction, and change sleep patterns4-8 
In the postoperative period, most adverse 
respiratory events occur during the first 24 
hours of opioid administration.2 During this 
period, pulse oximeter monitoring, 
supplemental oxygen, incentive spirometry, 
and intermittent nursing observation are the 
primary interventions used to fend off 
adverse respiratory events. For inpatient 
monitoring, pulse oximetry is often 
inadequate. On a busy hospital floor, it is 
difficult to respond to multiple remote 
advisory pulse oximetry alarms. Pulse 
oximeter alarms are ignored because they 
have a high false-positive alarm rate due to 
movement artifact and displacement.9,10 
Pulse oximetry primarily monitors 
oxygenation instead of ventilation; the SpO2 
signal is a delayed indicator for apnea or 
hypopnea, particularly when supplemental 
oxygen is given. By the time the pulse 
oximeter alarms, an apneic patient is 
already in danger of hypoxia, brain injury 
and death. 
Existing technologies may improve 
monitoring of adverse respiratory events in 
this setting, but are either costly or difficult 
to implement. For example, monitoring 
ventilation with capnography is expensive 
and it can be problematic to sample the 
exhaled gas with a face mask or nasal 
cannula in non-intubated patients.11 
Acoustic respiratory rate monitoring may be 
able to detect airway obstruction, but it is 
costly and may not have sufficient sensitivity 
to reliably detect apnea events.12 We 
suggest that there is an urgent need for a 
low cost, reliable respiratory depression 
monitoring technique that can be integrated 
with the signals from the pulse oximeter to 
give additional physiologic information about 
a patient’s sufficiency of both ventilation and 
oxygenation. 
Currently, we are exploring the value of 
integrating the information from a set of low-
cost physiologic monitors that can be 
adapted to monitoring patients. In addition 
to the red and infrared component signals 
that comprise the pulse oximeter 
plethysmography waveform, we intend to 
integrate information from motion sensors 
on the finger, head, abdomen, chest wall 
and bed, temperature, pressure and carbon 
dioxide sensors embedded in a nasal 
cannula and acoustic respiratory rate via a 
microphone on the throat. We will determine 
from the tested set the fewest number and 
least costly types of sensors that can be 
used to accurately identify and quantify 
ventilatory depression and airway 
obstruction, provide reliable measures of 
oxygenation AND ventilation, provide 
specific alarms, and avoid artifact. We will 
evaluate this multi-sensor set for volunteers 
who receive medications to produce 
ventilatory depression and/or partial to 
complete airway obstruction. 
Our team previously characterized various 
effects of sedatives combined with opioids 
using drug interaction models. Specifically, 
we characterized the interaction of Propofol 
and Remifentanil on metrics of airway 
obstruction and intolerable ventilatory 
depression in volunteers.8 We defined 
intolerable ventilatory depression as a 
respiratory rate less than 4 breaths per 
minute and airway compromise as either 
partial (tidal volume less than 3 mL/kg in the 
presence of a respiratory effort) or complete 
obstruction. Respiratory compromise was 
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defined as either intolerable ventilatory 
depression or airway obstruction or both.  
Using this model, predictions of respiratory 
compromise (0 to 100%) can be made for 
various dosing schemes of Propofol and 
remifentanil.8 (Figure 1).  In general, dosing 
schemes that led to high concentration of 
Propofol were more likely to produce airway 
obstruction and higher doses of 
Remifentanil were more likely to produce 
intolerable ventilatory depression.  
 
METHODS 
A 20 gauge venous catheter is placed in an 
antecubital vein under local anesthesia (0.2 
mL of 0.5% lidocaine) for the purpose of 
hydration and drug administration.  The IV 
site is similar in all subjects. A maintenance 
infusion of 0.9% sodium chloride is 
administered at 1 ml/kg/hour throughout the 
study. Continuous infusions of Remifentanil 
and Propofol are infused into this peripheral 
IV. 
Subjects are instrumented with a 
noninvasive blood pressure cuff, ECG 
leads, pulse oximeter(s), motion sensors, 
respiratory inductance plethysmography 
"chest bands", capnography nasal cannula, 
nasal gas pressure sensor, nasal thermistor 
and an acoustic respiratory rate sensor. 
These or similar monitors are placed to 
measure respiratory rate, tidal volume, end-
tidal CO2, SpO2, blood pressure, body 
motion and heart rate. Chest and abdominal 
wall excursion are measured with the 
attached motion sensors and the respiratory 
inductance plethysmography bands. 
Changes in respiration pattern will be 
displayed as real-time changes in CO2 
waveforms. A processed EEG monitor 
and/or a cerebral oximeter are optionally 
placed to record data for later analysis. A 
motion sensor may also be placed on the 
bed. These devices are operational during 
the entire study day. Data from devices is 
electronically captured and recorded for 
later analysis. Continuous variables such as 
motion waveforms, pulse oximetry 
waveform, capnogram, and nasal airway 
pressure are digitized during data collection 
periods at 50-1000Hz during data collection 
periods at each target effect site 
concentration pair. Discrete variables are 
recorded every 5 seconds or as soon as 
data are available during data collection 
periods. Examples of discrete variables 
Figure 1: A: Dose of a drug, first as a bolus, 
then as a continuous infusion. B: effect site 
concentration (Ce) Corresponding to the 
given dose and C: Observed effect 
(sedation) for a single administered drug. 
Time points 1-5 correspond to a likelihood of 
effect in D: Effect and corresponding drug 
concentrations resulting in stated 
probabilities for respiratory compromise.  
B 
C 
D 
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include heart rate, SpO2, PetCO2, systolic 
blood pressure, diastolic blood pressure and 
respiratory rate. The tidal volume may be 
occasionally measured with a differential 
pressure flow sensor attached to an 
anesthesia mask or mouthpiece in order to 
calibrate the respiratory inductance 
plethysmography bands. 
Each subject will receive Propofol and 
Remifentanil. Similar to previously collected 
data from our volunteer laboratory (Kern et 
al, 2004), each drug will be administered 
using a computer controlled (Stanpump14) 
continuous infusion pump (Pump 22; 
Harvard Apparatus, Limited, Holliston, MA) 
to achieve selected target effect site 
concentrations.  The effect site 
concentration refers to the drug 
concentration at the pharmacologic site of 
action. Pharmacokinetic parameters 
published by Minto et al.15 and Schnider et 
al.16 will be used for Remifentanil and 
Propofol respectively. 
We administer Propofol and Remifentanil 
pairs in a dose escalation scheme with 
small steps in order to creep up to the 
desired target effects of respiratory 
depression, airway obstruction and both 
effects while avoiding overshoot. To 
accomplish this, the Propofol is dosed in a 
range of 0.75 - 4 mcg/mL in dose escalation 
steps of approximately 0.5 mcg/mL. 
Remifentanil is dosed in a range of 0.75 to 
4.0 ng/mL in escalation steps of 
approximately 0.25-0.5 ng/mL. If overshoot 
is observed for a given target effect site 
concentration pair, the target effect site 
concentrations may be lowered so 
assessments can be made during the target 
effects of respiratory depression or airway 
obstruction or both. Once the drug 
concentration pair is identified which results 
in the target effects for a given subject, the 
steady state drug dose will be maintained 
for a period of data collection. 
RESULTS 
While the study is currently ongoing, a 
preliminary analysis of the data has 
revealed high correlation between certain 
respiratory monitors and specific breathing 
related ‘states’.  
These breathing states are ‘normal’ 
breathing, complete airway obstruction 
(obstructive sleep apnea), partial airway 
obstruction (partial obstructive sleep apnea 
or snoring), and ventilatory depression (non-
obstructive sleep apnea) characterized by a 
breathing rate of less than four breaths per 
minute. The figure below illustrates the 
some of the primary complex breathing 
patterns that we are interested in 
monitoring.  Ventilatory depression was not 
included in the figure as it appears in the 
form of intermittent ‘normal’ breathing with 
occasionally reduced volume.  
From this data we can already see multiple 
breathing patterns once we combine signals 
such as chest or abdomen band excursion 
(ventilatory effort) and nasal pressure, 
expired C02, or thermistor readings 
(ventilatory success). In column A, we see 
what we would expect for each of these 
signals under normal breathing conditions; 
The chest and abdomen are in phase with 
each other, the biphasic nasal pressure 
signal is synced with ventilatory effort, and 
the expired C02 increases at expiration.  
Column B of figure 2 illustrates how these 
signals change during airway obstruction; 
Chest and abdomen bands are out of phase 
with each other (paradoxical) while 
measures of ventilatory success are zeroed. 
Column C shows partial airway obstruction; 
the abdomen band becomes biphasic and 
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only syncs with the chest during the latter 
half of the breath attempt where the 
obstruction was partially cleared. The lower 
magnitude nasal pressure is one indicator of 
the patient’s difficulty passing air. 
Figure 3 shows an example of audio data 
recorded from a microphone attached to 
one side of the subject’s throat. Again we 
see the differences between normal 
breathing (A) and obstructed breathing (B). 
In the normal breathing case we see a 
generally lower magnitude, lower frequency 
sound as the passage of air is relatively 
quiet. Each breath has two distinct parts: 
inspiration and expiration. During obstructed 
breathing we see that the expiration phase 
is much lower in magnitude (or nonexistent 
in the second breath) because little or no air 
is passing. The first phase, however, is 
much higher in magnitude and frequency 
because the airway is restricted.   
 
 
 
 
 
 
 
Figure 2: Electronic signals collected during different breathing related ‘states’. The signals 
shown from top to bottom are: Chest band, abdomen band, nasal pressure, expired co2, 
and thermistor. The columns are one breath samples from the breathing states listed at the 
top of the figure. 
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CONCLUSION 
A low cost, accurate, and minimally sized 
respiratory monitor would be useful during 
space travel when personnel are limited 
following an injury/emergency procedure or 
if astronauts were to be sedated during 
extended voyages.  
Overall, preliminary analysis of the signals 
has been successful in proving that within 
individual patients, low cost signals exhibit 
discernible patterns during obstructive 
apnea, partial airway obstruction, and 
ventilatory depression. 
Unfortunately, the data set is slightly too 
small at the moment to draw statistically 
meaningful conclusions about the amount of 
patient to patient variation in signal shape. 
Potential variation in signal shape must be 
accounted for in any algorithm which 
attempts to identify breathing patterns and 
adverse respiratory events in a population 
of patients.  
 
 
As we collect more data, we hope to prove 
that the data patterns we have thus far 
identified persist through patients of variable 
age, gender, size, weight, and any other 
potentially confounding factors.  
ACKNOWLEDGEMENTS 
I would like to thank the Rocky Mountain 
Space Grant Consortium for providing 
funding in order to pursue this research. 
I would also like to thank those individuals 
who are currently assisting not only in data 
collection and planning but also in general 
advice during this study. Those individuals 
are Soeren Hoehne, Kelly Smith, Ken 
Johnson, and Julia White.  
REFERENCES 
1. Lynn LA, Curry JP. Patterns of unexpected in-
hospital deaths: a root cause analysis. Patient Saf 
Surg. 2011 Feb 11;5(1):3. 
2. Ramachandran SK, Haider N, Saran KA, Mathis M, 
Kim J, Morris M, O'Reilly M. Life-threatening critical 
respiratory events: a retrospective study of 
postoperative patients found unresponsive during 
Figure 3: Audio data from a microphone placed to the side of the subject’s throat. Both 
samples contain two breath attempts. Row A is an example of normal, unobstructed breathing. 
Row B is an example of partially obstructed breathing in the first breath and completely 
obstructed breathing in the second. 
2014 Rocky Mountain Space Grant Consortium                                                                                                                     7 
 
analgesic therapy. J Clin Anesth. 2011 
May;23(3):207-13. 
3. Jarzyna D, Jungquist CR, Pasero C, Willens JS, 
Nisbet A, Oakes L, Dempsey SJ, Santangelo D, 
Polomano RC. American Society for Pain 
Management Nursing guidelines on monitoring for 
opioid-induced sedation and respiratory depression. 
Pain Manag Nurs. 2011 Sep;12(3):118-145.e10. 
4. White DP. Opioid-induced suppression of 
genioglossal muscle activity: is it clinically important? 
J Physiol. 2009 Jul 15;587(Pt 14):3421-2. 
5. Berry RB, Kouchi K, Bower J, Prosise G, Light RW. 
Triazolam in patients with obstructive sleep apnea. 
Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 
1):450-4. 
6. Alattar MA, Scharf SM. Opioid-associated central 
sleep apnea: a case series. Sleep Breath. 2009 
May;13(2):201-6. Epub 2008 Sep 20. 
7. Finck AD, Berkowitz BA, Hempstead J, Ngai SH. 
Pharmacokinetics of morphine: effects of hypercarbia 
on serum and brain morphine concentrations in the 
dog. Anesthesiology. 1977 Nov;47(5):407-10. 
8. LaPierre C, Johnson K, Randall B, Egan T. (2011) 
Remifentanil-Propofol Effect-Site.Concentrations that 
Lead to Airway Obstruction and/or Intolerable 
Ventilatory Depression, A BOC11. In Proceedings of 
the 2011 Society for Technology in Anesthesia 
Annual Meeting. 
9. Gross B, Dahl D, Nielsen L. Physiologic monitoring 
alarm load on medical/surgical floors of a community 
hospital. Biomed Instrum Technol. 2011 
Spring;Suppl:29-36. 
10. Graham KC, Cvach M. Monitor alarm fatigue: 
standardizing use of physiological monitors and 
decreasing nuisance alarms. Am J Crit Care. 2010 
Jan;19(1):28-34. 
11. Hardman JG, Curran J, Mahajan RP. End-tidal 
carbon dioxide measurement and breathing system 
filters. Anaesthesia. 1997 Jul;52(7):646-8. 
12. Ramsay M.A., Lagow E., Usman M. Accuracy of 
Respiration Rate and Detection of Respiratory Pause 
by Acoustic Respiratory Monitoring in the PACU. 65th 
Annual Post Graduate Assembly in Anesthesiology. 
2011. New York, NY. 
13. Available from Steven L. Shafer, M.D., at 
http://www.opentci.org/doku.php?id=code:code. 
Posted November 25, 2008.  Last accessed April 27, 
2012. 
14. Minto CF, Schnider TW, Egan TD, Youngs E, 
Lemmens HJ, Gambus PL, Billard V, Hoke 
JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, 
Shafer SL. Influence of age and 
gender on the pharmacokinetics and 
pharmacodynamics of remifentanil. I. Model 
development. Anesthesiology 1997;86:10-23. 
15. Schnider TW, Minto CF, Shafer SL, Gambus PL, 
Andresen C, Goodale DB, Youngs EJ. 
The influence of age on propofol pharmacodynamics. 
Anesthesiology 1999;90:1502-16. 
16. Egan TD, Kern SE, Muir KT, White J. Remifentanil 
by bolus injection: a safety, pharmacokinetic, 
pharmacodynamic, and age effect investigation in 
human volunteers. Br. J. Anaesth. 2004 
Mar;92(3):335-43. 
 
 
